Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

COVID-19 Windfall Will Help Pfizer Remain Top Drug Company

Pfizer splits earnings on the vaccine evenly with BioNTech

Executive Summary

Pfizer said it expects its COVID-19 vaccine to generate $15bn in 2021, but the forecast appears to be an underestimation as it includes only contracted doses.

You may also be interested in...



How Pfizer Crafted Its Own ‘Operation Warp Speed’ For The COVID-19 Vaccine

It’s counter-intuitive, but not signing a commercial contract with BioNTech and refusing US federal funding were two of several moves Pfizer made to speed up development of its COVID-19 vaccine, CEO Albert Bourla says. Now it’s looking to supply low- and middle-income countries.

Quick Listen: Scrip’s Five Must-Know Things

Join us for an audio catch-up on the latest key developments in the worldwide biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things. 

Pfizer Says JAKs Have Their Place Despite Xeljanz Safety Issues

Management said it remains confident in Xeljanz and believes next-generation JAKs will be sufficiently differentiated. Pfizer's Vyndaqel and biosimilars businesses emerged as new blockbusters.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143744

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel